- OraSure Technologies Inc OSUR has resubmitted two separate Emergency Use Authorization (EUA) applications for its SARS-CoV-2 Antibody ELISA and the oral specimen collection device.
- ELISA is intended to qualitatively detect total antibodies to SARS-CoV-2 in human oral fluid specimens collected with the OraSure Oral Antibody Collection Device.
- Last year in December, the FDA requested additional information as part of its review of its EUA for the company's laboratory-based oral fluid Covid-19 antibody test.
- According to the SEC filing, the company has completed the necessary studies, collected the requested data, and, on May 21, submitted applications for the separate EUAs as requested by the FDA.
- Price Action: OSUR shares are up 5.9% at $9.89 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
